EFFICIENCY OF MULTICOMPONENT THERAPY IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (CLINICAL CASE)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Recently, glucagon-like peptide-1 agonists (GPP-1-a) are actively applied in the treatment of type 2 diabetes mellitus (DM2). To assess the effectiveness of exenatide treatment, multicentric international studies were conducted that have proven highly effective addition of the drug to metformin, sulfonylureas, and combinations thereof. A clinical experience of exenatide for the intensification of DM2 treatment, which showed that exenatide can be recommended for DM2 patients with overweight, glycated hemoglobin levels >7%, in case of ineffectiveness of the previous combination therapy.

Full Text

Restricted Access

About the authors

O. M Koteshkova

Email: koala58@mail.ru
SBHCI Endocrinological Dispensary of Moscow Healthcare Department Doctor of the highest qualification category, Head of the Department of Education and Treatment of Diabetes Mellitus

L. P Molina

SBHCI Endocrinological Dispensary of Moscow Healthcare Department

References

  1. Kimmei B., Inzucchi E.M. Oralagents for type 2 diabetes: an update. Clin. Diabetes. 2005; 23(2):64-76.
  2. Deacon C.F., Mannucci E., AhrenGlycaemic B. efficacy of glucagon like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors as add on therapy to metformin in subjects with type 2 diabetes a review and meta analysis. Diabetes Obes. Metab. 2012;14(8):762-67.
  3. Gregorio F., Ambrosi F., Manfrini S., et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabetic Medicine. 1999;16( 12):1016-24.
  4. Hirsch I.B., Bergenstal R.M. A real-worldapproach to insulin therapy in primary care practice. Clin. Diabetes. 2005;23(2):78-86.
  5. Zhao Y., Campbell C.R., Fonseca V., et al. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care. 2012;35(5): 1126-32.
  6. American Diabetes Association. Approaches to Glycemic Treatment. Diabetes Care. 2015;38(Suppl. 1):41-8.
  7. Inzucchi S.E, Bergenstal R.M., Buse J.B., et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38( 1 ): 140-49.
  8. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2015;18(Suppl. 1): 1-112.
  9. Викулова О.К., Шестакова М.В. Новые показания к терапии эксенатидом у больных сахарным диабетом 2 типа с ожирением. Diabetes Mellitus. 2010;3:98-104.
  10. Викулова О.К., Шестакова М.В. Клиническая эффективность миметика инкретинов экзенатида: результаты исследований и показания к применению у больных сахарным диабетом типа 2. Consilium Medicum. 2008;10(9):12-8.
  11. Nielsen L.L., Young A.A., Parkers D.G. Pharmacology of exenatide ( synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul. Rept. 2004;1177:77-88.
  12. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27( 11):2628-35.
  13. De Fronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin- treated patients with type 2 diabetes. Diabetes Care. 2005;28(5): 1092-100.
  14. Kendall D. M., Riddle C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-91.
  15. Ahren B. Incretin therapy of type 2 diabetes GLP-1 receptor agonists and DPP-4 inhibitors. Eur. Diabet. Nursing. 2013;10:31 -6.
  16. Cervera A., Wajcberg E., Sriwijitkamol A., Fernandez M., Zuo P., Triplitt C., Musi N., DeFronzo R.A., Cersosimo E. Mechanismofaction of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2008;294:846-52.
  17. Umapathysivam M.M., Lee M.Y., Jones K.L., Annink C.E., Cousins C.E., Trahair L. G., Rayner C.K. Comparative effects of prolonged and intermittent stimuiation of the giucagon-iikeрeptide 1 receptor on gastric empty in gandglycemia. Diabetes. 2014;63.785-90.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies